UK well being tech startup Zedsen has introduced a $12M (£8.7M) Series B spherical of funding at a $110 valuation.
The London-based agency makes non-invasive sensors which use key organic indicators from shoppers’ bloodstreams to offer personalised well being insights.
Investors embrace Joseph R Grano, former chairperson and CEO of UBS Financial Services Inc, Nasser Kazeminy, founding father of NJK Holding and chairperson of the Ellis Island Honor Society (EIHS), Tony Rice, former CEO of Cable and Wireless, Bonnie Mcalveen Hunter, chairperson of the Red Cross and Jim Harpel, investor at Palm Beach Capital.
Zedson additionally introduced that Caroline Hargrove, previously of Babylon Health and McLaren Applied Tech, has joined the agency as chief know-how officer (CTO).
WHAT IT DOES
Zedsen’s know-how makes use of a sensor that sits on the pores and skin to repeatedly collect biophysical information from the bloodstream with out the necessity for needles.
Most well being apps depend on information gleaned from outdoors the physique, resembling coronary heart fee, temperature and motion or get information from the blood invasively with needles or patches that puncture the pores and skin.
By analysing a mixture of inner and exterior information, Zedsen’s pores and skin sensor supplies customers a extra exact image of their well being to allow them to make small life-style modifications with vital long-term advantages.
The agency says its know-how may assist spot and reverse developments in direction of prediabetes, observe fertility, and perceive and tailor dietary must a person’s distinctive organic response. The know-how is supported by 46 patents.
WHAT IT’S FOR
A Zedsen spokesperson mentioned the funding can be used for brand spanking new product growth, analysis and growth (R&D) and advertising.
A personalised drugs method can also be being utilized by UK biotech agency Genomics plc, which is working with the NHS on a pilot study utilizing genetic info from sufferers’ blood samples to foretell threat of coronary heart illness.
Meanwhile, Fitbit customers can now track their blood glucose levels inside the gadget’s app, by connecting it with their LifeScan OneTouch Reveal app or manually logging their ranges. Fitbit plans so as to add different glucose meters and apps sooner or later.
ON THE RECORD
Zedsen CEO, Daniel Honeywell, mentioned: “Chronic disease accounts for 41 million avoidable deaths each year. Knowing this can be prevented through meaningful biological insights and manageable lifestyle changes will allow us to actually deliver on the promise of proactive, personalised and preventative care.”
Zedson CTO, Dr Hargrove, mentioned: “Low-cost, non-invasive technology for monitoring blood to a high standard is the holy grail that has profound, life-enhancing impact – whether you are monitoring metabolic health to improve athletic performance or working to reverse the trend towards diabetes. I’m delighted to be working on developing such transformative products based on Zedsen’s novel non-invasive technology and being part of Zedsen’s amazing team.”